Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No HPO annotations are available for this condition.
Most individuals with congenital erythropoietic porphyria (CEP) experience severe cutaneous photosensitivity in early infancy; the first manifestation is often pink-to-dark red discoloration of the urine. Hemolytic anemia is common and can be mild to severe, requiring chronic erythrocyte transfusions in some. The phenotypic spectrum ranges from severe (nonimmune hydrops fetalis) to milder disease (adult-onset with isolated cutaneous manifestations) . (See for variants that correlate with disease severity.) Skin. Cutaneous photosensitivity is present at birth or in early infancy and is characterized by blistering and increased friability of the skin over light-exposed areas. Bullae and vesicles are filled with serous fluid and are prone to rupture.
No consensus clinical diagnostic criteria for congenital erythropoietic porphyria (CEP) have been published. Suggestive Findings Congenital erythropoietic porphyria (CEP) should be suspected in individuals with the following clinical and laboratory findings and family history. Clinical findings • Nonimmune hydrops fetalis • Signs of congenital erythropoietic porphyria • Pink-to-dark red discoloration of the urine (pink or dark red urine-stained diapers are often the first sign in infants) • Hemolytic anemia • Severe cutaneous photosensitivity with onset usually in infancy or early childhood • Blisters and vesicles in light-exposed areas, which are prone to rupture and infection • Scarring and deformities (photomutilation) of digits and facial features, caused by recurrent blistering, infections, and bone resorption • In light-exposed areas: friable skin, skin thickening, hypo- and hyperpigmentation • Reddish-brown discoloration of teeth (fluoresce on exposure to long-wave ultraviolet light), also called erythrodontia • Corneal ulcers and scarring • Hypertrichosis of the face and extremities Laboratory findings include markedly increased levels of uroporphyrin I and coproporphyrin I isomers in erythrocytes, urine, or amniotic fluid as well as coproporphyrin I in stool . Table 1. Biochemical Characteristics of Congenital Erythropoietic Porphyria
No approved treatments are currently available for beta-thalassemia and related diseases. The disease remains an area of unmet medical need.
A management algorithm for congenital erythropoietic porphyria (CEP) has been published .
To establish the extent of disease and needs in an individual diagnosed with congenital erythropoietic porphyria (CEP), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Monitor the following:
Hematologic indices including iron profile, reticulocyte count, and bilirubin to assess hemolysis every six months
Note: Individuals receiving transfusion therapy need closer monitoring.
No clinical trials have been registered for beta-thalassemia and related diseases.
197 publications have been identified in PubMed for beta-thalassemia and related diseases. Research spans Review / Meta-Analysis (28%), Epidemiology / Natural History (20%), and Case Report / Case Series (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 56 | 28% |
Data assembled from 4 of 12 sources · Last updated Nov 17, 2026, 3:50 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Source: GeneReviews — "Congenital Erythropoietic Porphyria"
Enzyme Defect | Enzyme Activity1 | Tissue | Uroporphyrin1 | Coproporphyrin1 |
|---|---|---|---|---|
Uroporphyrinogen III synthase (URO-synthase)2 | Undetectable to ~10% of normal mean activity in erythrocytes | Erythrocytes | — | — |
Stool | Amniotic fluid3 | = markedly elevated The deficient activity of uroporphyrinogen III synthase EC 4.2.1.75, encoded by UROS, results in non-enzymatic conversion of hydroxymethylbilane to uroporphyrinogen I, which is then metabolized to coproporphyrinogen I. Coproporphyrinogen I cannot be metabolized further. | — | — |
Source: GeneReviews — "Congenital Erythropoietic Porphyria"
See for other disorders that present with a congenital erythropoietic porphyria (CEP)-like phenotype.
Table 3.
Disorders to Consider in the Differential Diagnosis of Congenital Erythropoietic Porphyria
Disease Name | Gene(s) | MOI | Clinical Features
Overlapping | Distinguishing
Porphyria cutanea tarda (PCT) type I (OMIM 176090) | See footnote 1. | • Cutaneous photosensitivity w/blistering friability of skin in sun-exposed areas
Facial hypertrichosis
Discolored urine
| • Usually manifests in adulthood
Distinct biochemical porphyrin profile
| UROD | AD
| UROD | AR | • Phenotype similar to PCT
Manifests in early childhood
Discolored urine
Photosensitivity
| • Distinct biochemical porphyrin profile
Developmental delay (in some)
Source: GeneReviews — "Congenital Erythropoietic Porphyria"
Biomarker and diagnostic research for beta-thalassemia and related diseases has been reported in the published literature.
Hematologic indices including reticulocytes and bilirubin (to assess hemolysis) and iron profile (to assess iron storage)
Serum calcium and vitamin D concentrations; bone densitometry
Hepatic function tests, especially in transfusion-dependent individuals given the risk for liver disease due to iron storage
Dermatologic evaluation to assess photosensitivity, photomutilation, and secondary skin changes (thickening, hyper- or hypopigmentation, hypertrichosis)
Ophthalmologic evaluation for corneal ulcers and scarring and other ocular manifestations
Dental assessment for erythrodontia (reddish-brown color from porphyrin deposition)
Consultation with a medical geneticist, certified genetic counselor, or certified advanced genetic nurse to inform affected individuals and their families about the nature, mode of inheritance, and implications of CEP in order to facilitate medical and personal decision making
Cutaneous photosensitivity. There is no FDA-approved treatment for this disease or specific treatment for the photosensitivity. Currently the only effective treatment is prevention o...
Source: GeneReviews — "Congenital Erythropoietic Porphyria"
The following are appropriate:
Avoidance of sunlight and UV light
In individuals with hepatic dysfunction, avoidance of drugs that may induce cholestasis (e.g., estrogens)
In individuals undergoing surgeries, use of protective filters for artificial lights in the operating room to prevent phototoxic damage
Source: GeneReviews — "Congenital Erythropoietic Porphyria"
Although there are no clinical trials at the present time, therapeutic approaches under investigation include phlebotomy or iron chelation strategies to reduce the hemolysis and decrease the accumulated porphyrins and, thus, photosensitivity [, , , ]. A murine CEP model is being used to investigate pharmacologic chaperone therapy (i.e., administration of small-molecule drugs to enhance the residual activity of mutated enzymes that have low activities or are unstable). Specifically, use of the antimicrobial agent ciclopirox as a chaperone-stabilized UROIII-synthase and reversed CEP-related findings such as abnormal URO I levels in the blood, splenomegaly, and liver porphyrins . Studies involving use of this medication in humans have not yet been performed. Search ClinicalTrials.
Source: GeneReviews — "Congenital Erythropoietic Porphyria"
View trials for beta-thalassemia and related diseases
Hepatic function every six to twelve months
Vitamin D 25-OH levels in all individuals whether or not they are receiving vitamin D supplements
Source: GeneReviews — "Congenital Erythropoietic Porphyria"
Disease patterns and progression
39 |
20% |
Patient case studies | 25 | 13% |
Laboratory research | 22 | 11% |
Clinical study results | 20 | 10% |
Testing and diagnosis research | 17 | 9% |
New treatment approaches | 17 | 9% |
Other research | 1 | 1% |
Nkya S (2026). [PMID: 41830511](https://pubmed.ncbi.nlm.nih.gov/41830511/). *Am J Hematol*. [Review / Meta-Analysis]
Ortega DC (2026). [PMID: 40873004](https://pubmed.ncbi.nlm.nih.gov/40873004/). *Ann Hum Genet*. [Epidemiology / Natural History]
Mishra V (2026). [PMID: 41943944](https://pubmed.ncbi.nlm.nih.gov/41943944/). *Hemoglobin*. [Epidemiology / Natural History]
Singh J (2026). [PMID: 41898808](https://pubmed.ncbi.nlm.nih.gov/41898808/). *Genes (Basel)*. [Case Report / Case Series]
Al Belbesi RY (2026). [PMID: 41869718](https://pubmed.ncbi.nlm.nih.gov/41869718/). *Biomed Res Int*. [Epidemiology / Natural History]
Brown D (2026). [PMID: 42054156](https://pubmed.ncbi.nlm.nih.gov/42054156/). *J Med Econ*. [Epidemiology / Natural History]
Zhang L (2026). [PMID: 41954743](https://pubmed.ncbi.nlm.nih.gov/41954743/). *Ann Hematol*. [Basic Science / Preclinical]
Al-Sanabra OM (2026). [PMID: 41685053](https://pubmed.ncbi.nlm.nih.gov/41685053/). *Therapeutic advances in hematology*. [Epidemiology / Natural History]
Nuin NA (2026). [PMID: 41987254](https://pubmed.ncbi.nlm.nih.gov/41987254/). *Malar J*. [Epidemiology / Natural History]
Kell PA (2026). [PMID: 41268862](https://pubmed.ncbi.nlm.nih.gov/41268862/). *J Pediatr Psychol*. [Epidemiology / Natural History]
AI-curated news mentioning beta-thalassemia and related diseases
Updated Nov 14, 2026
dural rosai dorfman disease in h syndrome expanding the neuropathologic spectrum of slc29a3 related disease
allergen specific antibodies dysregulation and profiles in igg4 related disease a hybrid case control and cross sectional study
expanding the phenotypic spectrum of pmpcb related disease long term survival with childhood onset ataxia
The FDA previously granted VOCERYQ both Orphan Drug and Breakthrough Therapy designations, and the European Commission granted INO-3107 Orphan Drug designation. "This new FDA-approved therapy brings us an important step closer to ensuring every RRP patient has access to a non-surgical treatment option that works for them. In reaching this milestone, we have shown that patient voices matter in the drug development process," said Kim McClellan, President of the RRP Foundation. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical studies, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial miles 30, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce the frequency of surgery in adults with RRP.
The Learning Collaborative also ... time to rare autoimmune disease diagnosis by 50% by 2036. "As a caregiver to my husband, Andy, who lives with IgG4-related disease, I know firsthand how overwhelming it can be to navigate a complex disease and find the right answers and care," said Kat Provencher, Director of Patient Advocacy, IgG4ward! Foundation... The Learning Collaborative also advances the goals of SPAARK (Strengthening Partnerships to Advance Autoimmune Rare Disease Knowledge), an Amgen-led alliance of 10 advocacy and professional organizations, including NORD, working toward reducing time to rare autoimmune disease diagnosis by 50% by 2036. "As a caregiver to my husband, Andy, who lives with IgG4-related disease, I know firsthand how overwhelming it can be to navigate a complex disease and find the right answers and care," said Kat Provencher, Director of Patient Advocacy, IgG4ward! Foundation. 27, 2026 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) today announced a major collaboration with Amgen to launch a Learning Collaborative through NORD's Rare Disease Centers of Excellence Network to reduce the time to diagnosis for rare disease, a significant gap in care. Through the pilot, clinicians from participating NORD Rare Disease Centers of Excellence will work with patients, caregivers and disease-specific advocacy organizations to examine where diagnosis, referrals, treatment decisions and care coordination break down. Founded in 1983, the National Organization for Rare Disorders (NORD®) is a leading independent, nonpartisan nonprofit dedicated to improving the health and lives of more than 30 million Americans with rare diseases. With more than 350 disease-specific member patient organizations and 49 designated Rare Disease Centers of Excellence spanning more than 170 affiliated institutions, NORD advances care, research, education and advocacy.